184 related articles for article (PubMed ID: 23497172)
1. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S; Horak P; Pils D; Pils S; Grimm C; Horvat R; Tong D; Schmid B; Speiser P; Reinthaller A; Polterauer S
BMC Cancer; 2013 Mar; 13():115. PubMed ID: 23497172
[TBL] [Abstract][Full Text] [Related]
2. Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations.
Grivas PD; Tzelepi V; Sotiropoulou-Bonikou G; Kefalopoulou Z; Papavassiliou AG; Kalofonos H
Cell Oncol; 2009; 31(3):235-47. PubMed ID: 19478391
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PELP1 in Lung Adenocarcinoma Promoted E
Zhang D; Dai J; Pan Y; Wang X; Qiao J; Sasano H; Zhao B; McNamara KM; Guan X; Liu L; Zhang Y; Chan MSM; Cao S; Liu M; Song S; Wang L
Pathol Oncol Res; 2021; 27():582443. PubMed ID: 34257530
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.
Kefalopoulou Z; Tzelepi V; Zolota V; Grivas PD; Christopoulos C; Kalofonos H; Maraziotis T; Sotiropoulou-Bonikou G
J Neurooncol; 2012 Jan; 106(1):23-31. PubMed ID: 21735116
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.
Vadlamudi RK; Balasenthil S; Broaddus RR; Gustafsson JA; Kumar R
J Clin Endocrinol Metab; 2004 Dec; 89(12):6130-8. PubMed ID: 15579769
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
[TBL] [Abstract][Full Text] [Related]
8. Altered Expression of
Englert-Golon M; Andrusiewicz M; Żbikowska A; Chmielewska M; Sajdak S; Kotwicka M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207568
[TBL] [Abstract][Full Text] [Related]
9. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
[TBL] [Abstract][Full Text] [Related]
10. Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells.
Pan Y; Wang X; Zhang Y; Qiao J; Sasano H; McNamara K; Zhao B; Zhang D; Fan Y; Liu L; Jia X; Liu M; Song S; Wang L
Horm Cancer; 2020 Apr; 11(2):87-96. PubMed ID: 32037484
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.
Tan W; Li Q; Chen K; Su F; Song E; Gong C
Oncotarget; 2016 Mar; 7(9):10373-85. PubMed ID: 26863572
[TBL] [Abstract][Full Text] [Related]
12. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
14. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.
Yang L; Ravindranathan P; Ramanan M; Kapur P; Hammes SR; Hsieh JT; Raj GV
Mol Endocrinol; 2012 Apr; 26(4):550-61. PubMed ID: 22403175
[TBL] [Abstract][Full Text] [Related]
15. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.
Vadlamudi RK; Balasenthil S; Sahin AA; Kies M; Weber RS; Kumar R; El-Naggar AK
Hum Pathol; 2005 Jun; 36(6):670-5. PubMed ID: 16021574
[TBL] [Abstract][Full Text] [Related]
16. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
18. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
19. Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
Flågeng MH; Knappskog S; Gjerde J; Lønning PE; Mellgren G
PLoS One; 2015; 10(8):e0134351. PubMed ID: 26247365
[TBL] [Abstract][Full Text] [Related]
20. PELP1 is a novel oncogene in gastric tumorigenesis and negatively regulated by miR-15 family microRNAs.
Ma C; Miao C; Wang C; Song F; Luo M
Cancer Biomark; 2019; 26(1):1-9. PubMed ID: 31322541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
